

Next-Generation Breast Cancer Diagnostic and Screening Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/NEB142941F33EN.html>

Date: February 2022

Pages: 100

Price: US\$ 3,250.00 (Single User License)

ID: NEB142941F33EN

Abstracts

This report contains market size and forecasts of Next-Generation Breast Cancer Diagnostic and Screening in Global, including the following market information:

Global Next-Generation Breast Cancer Diagnostic and Screening Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Next-Generation Breast Cancer Diagnostic and Screening market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Real-Time PCR (q-PCR) Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Next-Generation Breast Cancer Diagnostic and Screening include Abbott Laboratories, Agendia, Agilent Technologies, Ambry Genetics, Biocept, Biotheranostics, Centogene, Danaher Corporation and EXACT Sciences Corporation, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Next-Generation Breast

Cancer Diagnostic and Screening companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Next-Generation Breast Cancer Diagnostic and Screening Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Percentages, by Type, 2021 (%)

Real-Time PCR (q-PCR)

Immunohistochemistry (IHC)

Next-Generation Sequencing (NGS)

Fluorescent In-Situ Hybridization (FISH)

Global Next-Generation Breast Cancer Diagnostic and Screening Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Percentages, by Application, 2021 (%)

Hospital-associated Labs

Cancer Research Institutes

Diagnostic Centers

Global Next-Generation Breast Cancer Diagnostic and Screening Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Next-Generation Breast Cancer Diagnostic and Screening revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Next-Generation Breast Cancer Diagnostic and Screening revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Abbott Laboratories

Agendia

Agilent Technologies

Ambry Genetics

Biocept

Biotheranostics

Centogene

Danaher Corporation

EXACT Sciences Corporation

Roche Holding AG

Fulgent Genetics

Illumina

Invitae

Lucence Diagnostics Pte Ltd

Myriad Genetics

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Next-Generation Breast Cancer Diagnostic and Screening Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Next-Generation Breast Cancer Diagnostic and Screening Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC AND SCREENING OVERALL MARKET SIZE

- 2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size: 2021 VS 2028
- 2.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Next-Generation Breast Cancer Diagnostic and Screening Players in Global Market
- 3.2 Top Global Next-Generation Breast Cancer Diagnostic and Screening Companies Ranked by Revenue
- 3.3 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Companies
- 3.4 Top 3 and Top 5 Next-Generation Breast Cancer Diagnostic and Screening Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Next-Generation Breast Cancer Diagnostic and Screening

Product Type

3.6 Tier 1, Tier 2 and Tier 3 Next-Generation Breast Cancer Diagnostic and Screening Players in Global Market

3.6.1 List of Global Tier 1 Next-Generation Breast Cancer Diagnostic and Screening Companies

3.6.2 List of Global Tier 2 and Tier 3 Next-Generation Breast Cancer Diagnostic and Screening Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Markets, 2021 & 2028

4.1.2 Real-Time PCR (q-PCR)

4.1.3 Immunohistochemistry (IHC)

4.1.4 Next-Generation Sequencing (NGS)

4.1.5 Fluorescent In-Situ Hybridization (FISH)

4.2 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue & Forecasts

4.2.1 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2017-2022

4.2.2 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2023-2028

4.2.3 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2021 & 2028

5.1.2 Hospital-associated Labs

5.1.3 Cancer Research Institutes

5.1.4 Diagnostic Centers

5.2 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue & Forecasts

5.2.1 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2017-2022

5.2.2 By Application - Global Next-Generation Breast Cancer Diagnostic and

Screening Revenue, 2023-2028

5.2.3 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2021 & 2028

6.2 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue & Forecasts

6.2.1 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2017-2022

6.2.2 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2023-2028

6.2.3 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2017-2028

6.3.2 US Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.3.3 Canada Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.3.4 Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2017-2028

6.4.2 Germany Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.4.3 France Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.4.4 U.K. Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.4.5 Italy Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.4.6 Russia Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.4.7 Nordic Countries Next-Generation Breast Cancer Diagnostic and Screening

Market Size, 2017-2028

6.4.8 Benelux Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2017-2028

6.5.2 China Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.5.3 Japan Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.5.4 South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.5.5 Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.5.6 India Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2017-2028

6.6.2 Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.6.3 Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2017-2028

6.7.2 Turkey Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.7.3 Israel Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.7.4 Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

6.7.5 UAE Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Abbott Laboratories

7.1.1 Abbott Laboratories Corporate Summary

- 7.1.2 Abbott Laboratories Business Overview
- 7.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
- 7.1.4 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2017-2022)
- 7.1.5 Abbott Laboratories Key News
- 7.2 Agendia
 - 7.2.1 Agendia Corporate Summary
 - 7.2.2 Agendia Business Overview
 - 7.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
 - 7.2.4 Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2017-2022)
 - 7.2.5 Agendia Key News
- 7.3 Agilent Technologies
 - 7.3.1 Agilent Technologies Corporate Summary
 - 7.3.2 Agilent Technologies Business Overview
 - 7.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
 - 7.3.4 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2017-2022)
 - 7.3.5 Agilent Technologies Key News
- 7.4 Ambry Genetics
 - 7.4.1 Ambry Genetics Corporate Summary
 - 7.4.2 Ambry Genetics Business Overview
 - 7.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
 - 7.4.4 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2017-2022)
 - 7.4.5 Ambry Genetics Key News
- 7.5 Biocept
 - 7.5.1 Biocept Corporate Summary
 - 7.5.2 Biocept Business Overview
 - 7.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
 - 7.5.4 Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2017-2022)
 - 7.5.5 Biocept Key News
- 7.6 Biotheranostics

- 7.6.1 Biotheranostics Corporate Summary
- 7.6.2 Biotheranostics Business Overview
- 7.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
- 7.6.4 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2017-2022)
- 7.6.5 Biotheranostics Key News
- 7.7 Centogene
 - 7.7.1 Centogene Corporate Summary
 - 7.7.2 Centogene Business Overview
 - 7.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
 - 7.7.4 Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2017-2022)
 - 7.7.5 Centogene Key News
- 7.8 Danaher Corporation
 - 7.8.1 Danaher Corporation Corporate Summary
 - 7.8.2 Danaher Corporation Business Overview
 - 7.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
 - 7.8.4 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2017-2022)
 - 7.8.5 Danaher Corporation Key News
- 7.9 EXACT Sciences Corporation
 - 7.9.1 EXACT Sciences Corporation Corporate Summary
 - 7.9.2 EXACT Sciences Corporation Business Overview
 - 7.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
 - 7.9.4 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2017-2022)
 - 7.9.5 EXACT Sciences Corporation Key News
- 7.10 Roche Holding AG
 - 7.10.1 Roche Holding AG Corporate Summary
 - 7.10.2 Roche Holding AG Business Overview
 - 7.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
 - 7.10.4 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2017-2022)
 - 7.10.5 Roche Holding AG Key News

7.11 Fulgent Genetics

7.11.1 Fulgent Genetics Corporate Summary

7.11.2 Fulgent Genetics Business Overview

7.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings

7.11.4 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2017-2022)

7.11.5 Fulgent Genetics Key News

7.12 Illumina

7.12.1 Illumina Corporate Summary

7.12.2 Illumina Business Overview

7.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings

7.12.4 Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2017-2022)

7.12.5 Illumina Key News

7.13 Invitae

7.13.1 Invitae Corporate Summary

7.13.2 Invitae Business Overview

7.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings

7.13.4 Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2017-2022)

7.13.5 Invitae Key News

7.14 Lucence Diagnostics Pte Ltd

7.14.1 Lucence Diagnostics Pte Ltd Corporate Summary

7.14.2 Lucence Diagnostics Pte Ltd Business Overview

7.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings

7.14.4 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2017-2022)

7.14.5 Lucence Diagnostics Pte Ltd Key News

7.15 Myriad Genetics

7.15.1 Myriad Genetics Corporate Summary

7.15.2 Myriad Genetics Business Overview

7.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings

7.15.4 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2017-2022)

7.15.5 Myriad Genetics Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Next-Generation Breast Cancer Diagnostic and Screening Market Opportunities & Trends in Global Market

Table 2. Next-Generation Breast Cancer Diagnostic and Screening Market Drivers in Global Market

Table 3. Next-Generation Breast Cancer Diagnostic and Screening Market Restraints in Global Market

Table 4. Key Players of Next-Generation Breast Cancer Diagnostic and Screening in Global Market

Table 5. Top Next-Generation Breast Cancer Diagnostic and Screening Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Companies, 2017-2022

Table 8. Global Companies Next-Generation Breast Cancer Diagnostic and Screening Product Type

Table 9. List of Global Tier 1 Next-Generation Breast Cancer Diagnostic and Screening Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Next-Generation Breast Cancer Diagnostic and Screening Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Next-Generation Breast Cancer Diagnostic and Screening

Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2023-2028

Table 30. Abbott Laboratories Corporate Summary

Table 31. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product Offerings

Table 32. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), (2017-2022)

Table 33. Agendia Corporate Summary

Table 34. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product Offerings

Table 35. Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), (2017-2022)

Table 36. Agilent Technologies Corporate Summary

Table 37. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product Offerings

Table 38. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), (2017-2022)

Table 39. Ambry Genetics Corporate Summary

Table 40. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings

Table 41. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), (2017-2022)

Table 42. Biocept Corporate Summary

Table 43. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product Offerings

Table 44. Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), (2017-2022)

Table 45. Biotheranostics Corporate Summary

Table 46. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings

Table 47. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), (2017-2022)

Table 48. Centogene Corporate Summary

Table 49. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product Offerings

Table 50. Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), (2017-2022)

Table 51. Danaher Corporation Corporate Summary

Table 52. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product Offerings

Table 53. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), (2017-2022)

Table 54. EXACT Sciences Corporation Corporate Summary

Table 55. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product Offerings

Table 56. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), (2017-2022)

Table 57. Roche Holding AG Corporate Summary

Table 58. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product Offerings

Table 59. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), (2017-2022)

Table 60. Fulgent Genetics Corporate Summary

Table 61. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings

Table 62. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), (2017-2022)

Table 63. Illumina Corporate Summary

Table 64. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product Offerings

Table 65. Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), (2017-2022)

Table 66. Invitae Corporate Summary

Table 67. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product Offerings

Table 68. Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), (2017-2022)

Table 69. Lucence Diagnostics Pte Ltd Corporate Summary

Table 70. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product Offerings

Table 71. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), (2017-2022)

Table 72. Myriad Genetics Corporate Summary

Table 73. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings

Table 74. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Next-Generation Breast Cancer Diagnostic and Screening Segment by Type in 2021

Figure 2. Next-Generation Breast Cancer Diagnostic and Screening Segment by Application in 2021

Figure 3. Global Next-Generation Breast Cancer Diagnostic and Screening Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2021

Figure 8. By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2017-2028

Figure 9. By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2017-2028

Figure 10. By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2017-2028

Figure 11. By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2017-2028

Figure 12. US Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2017-2028

Figure 16. Germany Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 17. France Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2017-2028

Figure 24. China Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 28. India Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2017-2028

Figure 30. Brazil Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2017-2028

Figure 33. Turkey Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US\$, Mn), 2017-2028

Figure 37. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue

Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 51. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Next-Generation Breast Cancer Diagnostic and Screening Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/NEB142941F33EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NEB142941F33EN.html>